| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Review |
| Article Title |
Sodium glucose transporter 2 inhibitors for heart failure
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Daisuke Usuda, Daiki Furukawa, Rikako Imaizumi, Rikuo Ono, Yuki Kaneoka, Eri Nakajima, Masashi Kato, Yuto Sugawara, Runa Shimizu, Tomotari Inami, Riki Sakurai, Kenji Kawai, Shun Matsubara, Risa Tanaka, Makoto Suzuki, Shintaro Shimozawa, Yuta Hotchi, Ippei Osugi, Risa Katou, Sakurako Ito, Kentaro Mishima, Akihiko Kondo, Keiko Mizuno, Hiroki Takami, Takayuki Komatsu, Tomohisa Nomura and Manabu Sugita |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Japan Society for the Promotion of Science KAKENHI Grant |
No. JP24K15491 |
|
| Corresponding Author |
Daisuke Usuda, Associate Professor, MD, PhD, Department of Emergency and Critical Care Medicine, Juntendo University Nerima Hospital, 3-1-10 Takanodai, Nerima 177-8521, Tokyo, Japan. d.usuda.qa@juntendo.ac.jp |
| Key Words |
Sodium glucose transporter 2 inhibitor; Heart failure; Cardiovascular benefit; Mechanistic pathway; Current evidence; Prospects |
| Core Tip |
Heart failure (HF) affects over 64 million people worldwide, with persistently poor outcomes despite advances in treatment. Sodium glucose transporter 2 inhibitors, originally developed for diabetes, have emerged as breakthrough HF therapies with cardiovascular benefits beyond glucose control, including reduced risk of hospitalization and mortality. Landmark trials (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure, Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Reduced Ejection Fraction, Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction, Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) have demonstrated efficacy across all HF types, regardless of diabetes status. Their benefits stem from improved cardiac energetics, enhanced mitochondrial function, reduced oxidative stress and inflammation, and favorable cardiac remodeling. This review examines current evidence, mechanistic pathways, and future prospects for sodium glucose transporter 2 inhibitor use in cardiovascular medicine. |
| Citation |
Usuda D, Furukawa D, Imaizumi R, Ono R, Kaneoka Y, Nakajima E, Kato M, Sugawara Y, Shimizu R, Inami T, Sakurai R, Kawai K, Matsubara S, Tanaka R, Suzuki M, Shimozawa S, Hotchi Y, Osugi I, Katou R, Ito S, Mishima K, Kondo A, Mizuno K, Takami H, Komatsu T, Nomura T, Sugita M. Sodium glucose transporter 2 inhibitors for heart failure. World J Cardiol 2026; In press |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
